Expert FDA Meeting Preparation Services

A Type C FDA meeting is any meeting that does not fall under Type A or Type B categories. It is commonly used to discuss specific scientific, clinical, testing, regulatory, or submission issues that need FDA feedback. For medical device companies, Type C meetings can help clarify expectations, resolve development questions, and reduce uncertainty before major submission or change decisions.

Preparation timelines vary by meeting type and complexity, but most FDA meetings require several weeks of coordinated work. That typically includes evidence review, gap identification, question drafting, briefing package development, internal alignment, and mock meeting rehearsal. Complex devices, software-heavy products, or meetings involving clinical strategy often need more preparation time to ensure the package is complete, consistent, and strategically focused.

A company should request an FDA Pre-Sub meeting when it needs agency feedback before filing a formal submission, especially on testing strategy, predicate selection, clinical evidence, software documentation, labeling, or regulatory pathway. Requesting feedback early can prevent costly rework, reduce the risk of avoidable deficiencies, and help align internal teams around FDA expectations before timelines become compressed.

An FDA meeting briefing package should include a clear device overview, regulatory history, intended use, specific questions for FDA, supporting technical or clinical context, and any relevant testing or risk information. The package should be concise, logically organized, and written to help reviewers understand the issue quickly. Strong briefing packages focus on decision points rather than overwhelming the agency with unnecessary detail.

Mock FDA meetings help manufacturers rehearse likely reviewer questions, refine speaking roles, improve presentation flow, and identify weak points before the actual interaction. They are especially useful when multiple internal stakeholders are involved or when the discussion includes complex technical issues. A well-run mock session improves confidence, sharpens messaging, and reduces the chance of unclear or inconsistent responses during the live meeting.

Yes. Effective FDA meeting preparation can improve 510(k) outcomes by validating key assumptions before submission, such as predicate strategy, performance testing scope, software documentation expectations, and labeling positions. When manufacturers ask focused questions and present well-supported data, they are more likely to receive actionable feedback that strengthens the submission package and reduces the likelihood of delays caused by preventable Additional Information requests.

After an FDA meeting, the company should review the discussion carefully, confirm action items, and align next steps with the feedback received. This may involve updating the regulatory strategy, revising testing plans, remediating documentation gaps, or preparing a formal submission. Meeting outcomes are most valuable when they are translated into a documented execution plan with responsibilities, timelines, and clear regulatory rationale.

Yes. Elexes supports FDA meeting preparation as well as broader regulatory strategy across multiple authorities, including Health Canada, TGA, EU MDR, and other global frameworks. For companies managing multi-market plans, this is valuable because FDA meeting positions often affect documentation, testing, and claims used elsewhere. The team helps ensure your FDA interaction supports a coherent overall regulatory pathway rather than creating downstream conflicts.